Specialized Resource A - Cyclotron Radiochemistry and Chemistry (SR-A). lCMlC-3 is reliant on the production and supply of existing and novel radiopharmaceuticals and radiochemicals. In this Specialized Resource we will continue to generate a tool box of radiolabeled drugs based around 18F-tracers as well as drugs based on the longer-lived nuclides 64Cu, 86Y, 89Zr and 1241. This will allow us to augment the existing lCMIC-3 projects, the ICMIC Developmental Projects, ultimately resulting in the ability to get a better understanding of the biology of cancer and to perform personalized medicine in our patients.
The Specific Aims of this Specialized Resource are as follows: (A) to undertake specialized radiochemistry and labeling chemistry in support of the ICMIC projects and developmental projects; (B) To function as an evolving resource - to provide (and design) new compounds as required as the ICMIC research matures; and, (C) to act as a central resource for the translation of new drugs to the clinical setting.

Public Health Relevance

This Specialized Resource will provide services and expertise in chemistry and radiochemistry to all four of the Research Projects within this ICMIC. This Specialized Resource we will generate a tool box of radiolabeled drugs that will allow us to augment the existing ICMIC projects, the ICMIC developmental projects and the new ICMIC research programs, ultimately resulting in the ability to get a better understanding of the biology of cancer and to perform personalized medicine in our patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA086438-12
Application #
8555297
Study Section
Special Emphasis Panel (ZCA1-SRLB-9 (M1))
Project Start
2000-06-01
Project End
2016-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
12
Fiscal Year
2012
Total Cost
$203,215
Indirect Cost
$91,910
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629
Dunphy, Mark P S; Harding, James J; Venneti, Sriram et al. (2018) In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine. Radiology 287:667-675
Graham, Nicholas A; Minasyan, Aspram; Lomova, Anastasia et al. (2017) Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Mol Syst Biol 13:914
Lu, Shaohua; Tan, Kay See; Kadota, Kyuichi et al. (2017) Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma. J Thorac Oncol 12:223-234
Pankov, Dmitry; Sjöström, Ludvig; Kalidindi, Teja et al. (2017) In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). Oncotarget 8:65917-65931
Kim, Kwanghee; Zhang, Hanwen; La Rosa, Stephen et al. (2017) Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy. Clin Cancer Res 23:3343-3351
Shrestha, Liza; Patel, Hardik J; Kang, Yanlong et al. (2017) Copper Mediated Coupling of 2-(Piperazine)-pyrimidine Iodides with Aryl Thiols using Cu(I)Thiophene-2-carboxylate. Tetrahedron Lett 58:4525-4531
Lee, Jason T; Zhang, Hanwen; Moroz, Maxim A et al. (2017) Comparative Analysis of Human Nucleoside Kinase-Based Reporter Systems for PET Imaging. Mol Imaging Biol 19:100-108
Weidenauer, Lorenz; Wang, Tai; Joshi, Suhasini et al. (2017) Proteomic interrogation of HSP90 and insights for medical research. Expert Rev Proteomics 14:1105-1117
Serganova, Inna; Moroz, Ekaterina; Cohen, Ivan et al. (2017) Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade. Mol Ther Oncolytics 4:41-54

Showing the most recent 10 out of 191 publications